Treatment > Carmustine


Astrocytomas


Mathieu NT, Genet D, Labrousse F, Bouillet P, Denes SL, Martin J, Labourey JL, Venat L, Clavere P, Moreau JJ
Pre-irradiation chemotherapy for newly diagnosed high grade astrocytoma
Anticancer Res. 2004 Mar-Apr;24(2C):1249-53


Brain Tumors


William J. Bodell, Alexander P. Bodell, Donald D. Giannini
Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol)
Neuro-oncol 2006,
Epub 2006 Oct 3. DOI:10.1215/15228517-2006-014

William J. Bodell, Donald D. Giannini, Saira Singh, Dennis Pietronigro, Victor A. Levin
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015
Journal of Neuro-Oncology
, 62 (3): 251-258, May 2003

Plowman J, Waud WR, Koutsoukos AD, Rubinstein LV, Moore TD, Grever MR
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea
Cancer Res 1994 Jul 15;54(14):3793-9

Prados MD, Larson DA, Lamborn K, McDermott MW, Sneed PK, Wara WM, Chang SM, Mack EE, Krouwer HG, Chandler KL, Warnick RE, Davis RL, Rabbitt JE, Malec M, Levin VA, Gutin PH, Phillips TL, Wilson CB
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors
Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63


Glioblastoma


Balana C, Ramirez JL, Taron M, Roussos Y, Ariza A, Ballester R, Sarries C, Mendez P, Sanchez JJ, Rosell R
O(6)-methyl-guanine-DNA methyltransferase Methylation in Serum and Tumor DNA Predicts Response to 1,3-Bis(2-Chloroethyl)-1-Nitrosourea but not to Temozolamide Plus Cisplatin in Glioblastoma Multiforme
Clin Cancer Res 2003 Apr;9(4):1461-8

Lorena Bissola, Marica Eoli, Francesca Menghi, Bianca Pollo, Antonio Silvani, Giovanni Broggi, Amerigo Boiardi, Gaetano Finocchiaro
MGMT promoter hypermethylation is more frequent in secondary glioblastomas and is independent from other prognostic factors
Proceedings of the AACR, Volume 45, March 2004. Abstract Number: 1077

A. A. Brandes, MD, A. Tosoni, MD, P. Amistà, MD, L. Nicolardi, MD, D. Grosso, RN, F. Berti, MD and M. Ermani, MD
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
Neurology,  Oct 12, 2004;63:1281-1284

A. A. Brandes, A. Tosoni, M. Reni, F. Valduga, U. Basso, S. Lonardi, L. M. Pasetto, V. Blatt, S. Monfardini, M. Ermani
Second line BCNU plus CPT-11 chemotherapy in recurrent glioblastoma (GBM): Phase II study of GICNO (Italian Neuro-Oncology Group)
40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1516

Alba Ariela Brandes, Mario Ermani, Umberto Basso, Lara Maria Pasetto, Francesca Vastola, Franco Berti, Silvia Berlucchi, Pietro Amistà, Antonello Rotilio, Silvio Monfardini
Procarbazine Prior to and Concomitant with BCNU in Patients with Glioblastoma at First Relapse: a Phase II Study
ASCO Proceedings, 2001 Annual Meeting, Abstract 


R. Cardinale, M. Won, A. Choucair, M. Gillin, A. Chakravarti, C. Schultz, L. Souhami, A. Chen, H. Pham and M. Mehta
A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RTOG-0023
2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1511. 
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1511


O. Chinot, M. Barrie, C. Couprie, H. Dufour, D. Figarella, X. Muracciole, D. Braguer, K. Hoang-Huan, J.-C. Peragut, F. Grisoli
Preradiation combination of temozolomide (TMZ) and BCNU as primary treatment before radiotherapy (RT) in inoperable newly diagnosed glioblastoma multiforme (GBM)
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 431

Alf Giese, Thomas Kucinski, Ulrich Knopp, Roland Goldbrunner, Wolfgang Hamel, H.M. Mehdorn, Jörg C. Tonn, Dana Hilt, Manfred Westphal
Pattern of Recurrence following Local Chemotherapy with Biodegradable Carmustine (BCNU) Implants in Patients with Glioblastoma
Journal of Neuro-Oncology, 66 (3): 351-360, February 2004

K. A. Jaeckle, K. V. Ballman, P. Schomberg, J. Uhm, B. Schiethauer, C. Giannini, S. Felton, P. Brown, B. C. Jan NCCTG
N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study
2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1514


Khoshyomn S, Nathan D, Manske GC, Osler TM, Penar PL
Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells
J Neurooncol 2002 May;57(3):193-200 

C. Linassier, M. Ben Hassel, D. Figarella-Branger, J.-O. Bay, H. Bourgeois, T. Lesimple, J.-P. Cottier, L. Taillandier, R. Delepine, D. Frappaz
Phase III study comparing high-dose BCNU with autologous blood stem cell support versus standard dose BCNU, in combination with radiotherapy after gross total resection in patients with supratentorial glioblastoma
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No. 399 

Timothy J Moynihan, Judith R O'Fallon, J. E Krook, Paula Schomberg, Robert P Dinapoli, I. Kazem, Bernd Scheithauer, Jan C Buckner
A phase II trial of pre-irradiation chemotherapy with BCNU, cisplatin and oral etoposide combined with radiation therapy in the treatment of glioblastoma (GBM)
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No.
306  


Napolitano M, Keime-Guibert F, Monjour A, Lafitte C, Ameri A, Cornu P, Broet P, Delattre JY
Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study
J Neurooncol 1999;45(3):229-35 

Nicolardi L, Deangelis LM
Response to chemotherapy of a radiation-induced glioblastoma multiforme
J Neurooncol. 2005 Nov 29;1-3 [Epub ahead of print]

Pan E, Mitchell SB, Tsai JS
A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients
J Neurooncol. 2008 Apr 4; [Epub ahead of print]
 Abstract |
DBLinks | BL 7:8

Michael D. Prados, W.K. Alfred Yung, Howard A. Fine, Harry S. Greenberg, Larry Junck, Susan M. Chang, M. Kelly Nicholas, H. Ian Robins, Minesh P. Mehta, Karen L. Fink, Kurt A. Jaeckle, John Kuhn, Kenneth R. Hess, and S. Clifford Schold Jr.
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
Neuro-Oncology, January 2004, Volume 6 Number 1, Pages 33 -- 37 

Schold SC Jr, Kuhn JG, Chang SM, Bosik ME, Robins HI, Mehta MP, Spence AM, Fulton D, Fink KL, Prados MD.
A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study
Neuro-oncol 2000 Jan;2(1):34-9 

Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R, Schultz CJ, Sause W, Okunieff P, Buckner J, Zamorano L, Mehta MP, Curran WJ Jr
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60. 

Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D
Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series
Neurosurgery 1999 Jul;45(1):17-22 

Emil L. Weber and Eric A. Goebel
Cerebral edema associated with Gliadel wafers: Two case studies
Neuro-Oncology, Volume 7, Number 1, Pages 84 -- 89, January 2005. (Abstract+)


Gliomas


Aas AT, Brun A, Pero RW, Salford LG.
Chlorpromazine in combination with nitrosourea inhibits experimental glioma growth.
Br J Neurosurg 1994;8(2):187-92  

Mary L Affronti, David Reardon, Deborah Allen, Rodney Beason, Sridharan Gururangan, Allan Friedman, James Herndon, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Amy Walker, Darell D Bigner, Henry Friedman
A phase II study of CPT-11 plus BCNU for adults with high grade glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No.
2091  


Beith J., Cook R., Robinson B., Levi J., Bell D., Wheeler H. 
Modulation of resistance to BCNU by depleting MGMT activity with procarbazine in patients with relapsed high-grade gliomas

ASCO Proceedings, 1997 Annual Meeting, Abstract No. 1375 

Bowles AP Jr, Pantazis CG, Wansley W
Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study
J Neurosurg 1990 Aug;73(2):248-53 

Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al.
Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group
Lancet 1995 Apr 22;345(8956):1008-12 


Chang SM, Prados MD, Yung WK, Fine H, Junck L, Greenberg H, Robins HI, Mehta M, Fink KL, Jaeckle KA, Kuhn J, Hess K, Schold C
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
Cancer. 2004 Apr 15;100(8):1712-6. 

S. M. Chang, W. K. A. Yung, J. Kuhn, D. Schiff, H. Fine, M. Mehta, I. Robins, L. Junck, K. Hess, M. Prados
Phase II study of neoadjuvant BCNU and temozolomide for newly diagnosed anaplastic glioma
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 413 

Engelhard HH
The role of interstitial BCNU chemotherapy in the treatment of malignant glioma
Surg Neurol. 2000 May; 53(5): 458-64. 

Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
N Engl J Med 2000 Nov 9;343(19):1350-4
 

Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N, Figg WD, Purow BW, Borkowf CB
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
J Clin Oncol. 2003 Jun 15;21(12):2299-304  

Friedman HS, Keir S, Pegg AE, Houghton PJ, Colvin OM, Moschel RC, Bigner DD, Dolan ME
O6-benzylguanine-mediated enhancement of chemotherapy
Mol Cancer Ther 2002 Sep;1(11):943-8 

Allan H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman
Novel use of Gliadel for gliomas

38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.  

Maria Gonzalez Cao, Javier Aristu, Marta Santisteban, Jose M Ordonez, Jose M Aramendia, Ignacio Bilbao, Oscar Fernandez, Salvador Martin Algarra
Phase II trial of BCNU, temozolamide (TMZ) plus intraarterial cisplatin (CDDP) in unresectable or recurrent high grade glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No. 2099 

Gururangan S, Cokgor L, Rich JN, Edwards S, Affronti ML, Quinn JA, Herndon JE 2nd, Provenzale JM, McLendon RE, Tourt-Uhlig S, Sampson JH, Stafford-Fox V, Zaknoen S, Early M, Friedman AH, Friedman HS.
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas
Neuro-oncol 2001 Oct;3(4):246-50 


Hamstra DA, Moffat BA, Hall DE, Young JM, Desmond TJ, Carter J, Pietronigro D, Frey KA, Rehemtulla A, Ross BD
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study
J Neurooncol. 2005 Jul;73(3):225-38. (Laboratory Investigation, Abstract)

Kleinberg LR, Weingart J, Burger P, Carson K, Grossman SA, Li K, Olivi A, Wharam MD, Brem H
Clinical course and pathologic findings after Gliadel and radiotherapy for newly diagnosed malignant glioma: implications for patient management
Cancer Invest. 2004;22(1):1-9. 

Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB
Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report
Int J Radiat Oncol Biol Phys 1990 Feb;18(2):321-4 

P. Z. New, S. Grossman, T. Mikkelsen, T. Batchelor, S. Phuphanich, K. Carson, J. Fisher, M. Craig, P. Cagnoni
Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial
40th ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1533 

Pamela Z New, Stuart A Grossman, Tracy Batchelor, Fred Hochberg, Surasak Phuphanich, Kathryn Carson, Regina Priett
Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: preliminary data of NABTT 9806 phase I/II clinical trial
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 2098  

Perry J, Chambers A, Spithoff K, Laperriere N.
Gliadel wafers in the treatment of malignant glioma: a systematic review.
Curr Oncol. 2007 Oct;14(5):189-94.
Full Text | Reprint

Jennifer A. Quinn, David A. Reardon, Allan H. Friedman, Jeremy N. Rich, John H. Sampson, James Vredenburgh, Sridharan Gururangan, James M. Provenzale, Amy Walker, Holly Schweitzer, Darell D. Bigner, Sandra Tourt-Uhlig, James E. Herndon II, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Cindy Bohlin, Christy Lentz, Henry S. Friedman
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma
Neuro-Oncology, April 2004 Volume 6, Number 2, Pages 145 – 153. (Abstract+)

Jennifer A. Quinn, M. Eileen Dolan, Anthony E. Pegg, Robert C. Moschel, James Pluda, Roger E. McLendon, James Provenzale, William Petros, Sandra Tourt-Uhlig, Jeremy N. Rich, Sridharan Gururangan, Mary L. Affronti, Waynette Buchanan, O. Michael Colvin, Elizabeth S. Stewart, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase II Trial of BCNU Plus O6-Benzylguanine for Patients with Recurrent or Progressive Malignant Glioma
ASCO Proceedings, 2001 Annual Meeting, Abstract No.251
 

Jeffrey J. Raizer, Mark G. Malkin, Martin Kleber, Lauren E. Abrey
Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy
Neuro-Oncology, July 2004, Vol. 6, No. 3, 247 -- 252. (Abstract+)

David A. Reardon, Jennifer A. Quinn, Jeremy N. Rich, Sridharan Gururangan, James Vredenburgh, John H. Sampson, James M. Provenzale, Amy Walker, Michael Badruddoja, Sandra Tourt-Uhlig, James E. Herndon II, Jeannette M. Dowell, Mary Lou Affronti, Susanne Jackson, Deborah Allen, Karen Ziegler, Steven Silverman, Cindy Bohlin, Allan H. Friedman, Darell D. Bigner, Henry S. Friedman
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
Neuro-Oncology, April 2004, Volume 6, Number 2, Pages 134 – 144. (Abstract+)

Mark Rosenblum, J Weingart, Eileen Dolan, S Tatter, K Judy, J Olson, E Bohan, J Fisher
Phase I study of Gliadel combined with a continuous intravenous infusion of O6-benzylguanine in patients with recurrent malignant glioma
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract No. 314 

Slancar M., Wheeler H., Cook R., Levi J., Bell D., Beith J.
Increased pulmonary toxicity with scheduling procarbazine prior to BCNU in patients with high-grade gliomas

ASCO Proceedings, 1997 Annual Meeting, Abstract No. 1459 

The Brain Tumor Cooperative Group ; Robert G. Selker, M.D.; William R. Shapiro, M.D.; Peter Burger, M.D.; Margaret S. Blackwood, M.S.; Melvin Deutsch, M.D.; Vincent C. Arena, Ph.D.; John C. Van Gilder, M.D.; Julian Wu, M.D.; Mark G. Malkin, M.D.; John Mealey, Jr., M.D.; John H. Neal, M.D.; Jeffrey Olson, M.D.; James T. Robertson, M.D.; Gene H. Barnett, M.D.; Stephen Bloomfield, M.D.; Robert Albright, M.D.; Fred H. Hochberg, M.D.; Emile Hiesiger, M.D.; Sylvan Green, M.D.
The Brain Tumor Cooperative Group NIH Trial 87-01: A Randomized Comparison of Surgery, External Radiotherapy, and Carmustine versus Surgery, Interstitial Radiotherapy Boost, External Radiation Therapy, and Carmustine
Neurosurgery 2002 Aug;51(2):343-55
 Abstract |
  DBLinks | BL 1:2

Soma MR, Pagliarini P, Butti G, Paoletti R, Paoletti P, Fumagalli R
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells

Cancer Res 1992 Aug 15;52(16):4348-55 


Mark M. Souweidane, Giuseppe Occhiogrosso, Erika B. Mark, Mark A. Edgar, Ira J. Dunkel
Interstitial Infusion of Carmustine in the Rat Brain Stem with Systemic Administration of
O6-benzylguanine
Journal of Neuro-Oncology,
67 (3): 319-326, May 2004. (Abtract+)

Tatter SB, Shaw EG, Rosenblum ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA; New Approaches to Brain Tumor Therapy Central Nervous System Consortium
An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial
J Neurosurg. 2003 Aug;99(2):297-303  

Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T
Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study
Neurosurgery 1997 Jul;41(1):44-8 

Meg Verrees, Lili Liu, Stanton L. Gerson
Interruption of base excision repair selectively enhances temozolamide and 1,3-bis(2-chloroethyl)-nitrosurea cytotoxicity in treatment of adult human malignant glioma cell lines
Proceedings of the AACR, Volume 45, March 2004, Abstract Number: 1548

M. Westphal, Z. Ram, V. Riddle, D. Hilt, E. Bortey and On behalf of the Executive Committee of the Gliadel® Study Group
Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial
Acta Neurochirurgica, Volume 148, Number 3, March 2006; DOI: DOI: 10.1007/s00701-005-0707-z
Abstract | BrainLife | News News

Manfred Westphal, Dana C. Hilt, Enoch Bortey, Patrick Delavault, Robert Olivares, Peter C. Warnke, Ian R. Whittle, Juha Jääskeläinen, Zvi Ram
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma
Neuro-Oncology,
April 2003, Volume 5, Number 2, Page: 79 -- 88 

Wolff JE, Berrak S, Koontz Webb SE, Zhang M
Nitrosourea efficacy in high-grade glioma: a survival gain analysis summarizing 504 cohorts with 24193 patients
J Neurooncol. 2008 Feb 6; [Epub ahead of print]
Abstract |
DBLinks | BL 7:4


Medulloblastoma


Demetrius M. Kokkinakis, Robert C. Moschel, Anthony E. Pegg and S. Clifford Schold
Eradication of Human Medulloblastoma Tumor Xenografts with a Combination of O6-Benzyl-2'-deoxyguanosine and 1,3-Bis(2-chloroethyl)-1-nitrosourea
Clinical Cancer Research Vol. 5, 3676-3681, November 1, 1999. (PDF Full Text)


Oligoastrocytomas


Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, Silvani A
Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas
J Neurooncol 2000 Aug;49(1):71-5  


Oligodendroglioma


Richard A. Lytle, Zhihong Jiang, Xiao Zheng, Keith M. Rich
BCNU Down-Regulates Anti-Apoptotic Proteins Bcl-xL and Bcl-2 in Association with Cell Death in Oligodendroglioma-Derived Cells
Journal of Neuro-Oncology,
68 (3): 233-241, July 2004. (Abstract+)


Primary CNS Lymphoma


Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G, Frickhofen N, Feuerhake F, Volk B, Finke J.
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
J Clin Oncol. 2006 Aug 20;24(24):3865-70. Epub 2006 Jul 24.
Abstract


Pituitary Adenomas


Laws ER Jr, Morris AM, Maartens N
Gliadel for pituitary adenomas and craniopharyngiomas
Neurosurgery. 2003 Aug;53(2):255-69; discussion 259-60



Tumors


Dolan ME, Pegg AE
O6-benzylguanine and its role in chemotherapy
Clin Cancer Res 1997 Jun;3(6):837-47 

 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
|
Children's Corner | E-mail Alerts | Journals | Newsletter | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP